Skip to content
Screener

Viatris VTRS Net debt / EBITDA

Net debt / EBITDA at other companies

Pfizer logo
PfizerPFE
3.8×—
McKesson logo
McKessonMCK
-0.3×-0.9×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-0×-2.5×
Cencora logo
CencoraCOR
2.6×+1.2×
AMP
Amphastar PharmaceuticalsAMPH
3×+1.1×
Merck & Co. logo
Merck & Co.MRK
3×+1.7×

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$20.45B+94.9%
Enterprise value$33.26B+34.7%
P/S1.4×+0.7×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%—
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity1×+0.1×
Current ratio1.6×-0.1×

Where this comes from

Calculated from Viatris’s reported figures.

net debt/ebitda=4.3×

Based on the most recent quarter.

The source filing: Viatris’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001792044-26-000029

FAQ

What is Viatris's net debt / EBITDA?
Viatris (VTRS) reported net debt / EBITDA of 4.3× in Q1 2026.
What is the long-term trend for Viatris's net debt / EBITDA?
Over 4 years (2020 to 2025), Viatris's net debt / EBITDA has grown at a 71.3% compound annual growth rate (CAGR), from 11.5× to 98.8×.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.

Ask your AI about Viatris's net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude